In the Original Investigation titled “Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies,”1 published in the February 2020 issue, the y-axis was incorrect in the Figure. The data should span 87% to 100% rather than 15% to 100%. This article has been corrected online.
Reference
- 1.Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365 [DOI] [PMC free article] [PubMed] [Google Scholar]